Almut Winterstein
Distinguished Professor | University of Florida
Gainesville, FL, UNITED STATES
Almut Winterstein is an expert in drug safety and ways to improve medication use.
Biography
Almut Winterstein is a distinguished professor and chair of the Department of Pharmaceutical Outcomes and Policy in the College of Pharmacy. She is the founding director of the Center for Drug Evaluation and Safety. Almut is co-leader of the state of Florida's Consortium for Medical Marijuana Clinical Outcomes Research. She is an expert in drug safety and ways to improve medication use. Almut's research interests have centered on the post-marketing evaluation of drugs in pediatrics and perinatal care, infectious disease and psychiatry and the evaluation and improvement of quality surrounding medication use using real-world data.
Areas of Expertise (10)
Medical Marijuana
Healthcare Quality
Drug Use in Maternal and Child Health
Medical Marijuana Safety
Pharmacoepidemiology
Drug Safety
Patient Safety
Medical Marijuana Effectiveness
Teratogenic Drug Effects
Risk Mitigation of Adverse Drug Effects
Media Appearances (2)
UF study finds 1 in 16 women take harmful drugs during pregnancy
UF College of Pharmacy online
2022-02-10
In a review of more than 3 million pregnancies, University of Florida researchers found 1 in 16 women were exposed to harmful teratogenic drugs — medications that can cause pregnancy loss, birth defects and other health problems for the unborn child. The study published in the American Journal of Obstetrics and Gynecology highlights the need for women and their providers to carefully examine medications taken during pregnancy.
FDA Panels Say Risks of Opana ER Outweigh Benefits
Medscape online
2017-03-17
A panel of US Food and Drug Administration (FDA) experts has advised the agency that the risks of an abuse-deterrent extended-release formulation of oxymorphone (Opana ER, Endo Pharmaceuticals) for relief of severe pain now outweigh its benefits.
Articles (4)
CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
Journal of the American Heart AssociationAmber L. Beitelshees, et al.
2022-02-12
Studies have demonstrated increased risk of major atherothrombotic events in CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with clopidogrel after percutaneous coronary intervention (PCI). We sought to evaluate real‐world outcomes with the clinical implementation of CYP2C19‐guided antiplatelet therapy after PCI.
Discontinuation of Long-Term Opioid Therapy in Patients With Versus Without Dementia
American Journal of Preventive MedicineYu-Jung J. Wei, Cheng Chen and Almut G. Winterstein
2022-02-01
Discontinuation of long-term opioid therapy has increased in recent years, but whether this trend extends to patients with Alzheimer disease and related dementia remains unclear.
Generalizability and accuracy of IBM MarketScan health risk assessment instrument data for augmentation of commercial claims data
Pharmacoepidemiology & Drug SafetyYasser Albogami, Yu-Jung J. Wei and Almut G. Winterstein
2021-10-17
We evaluated the generalizability and accuracy of the IBM® MarketScan® Health Risk Assessment (HRA) data to assess its suitability as supplement to linked claims data.
A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019
Medical Cannabis and CannabinoidsS. Jugl, et al.
2021-06-01
In 2017, a National Academies of Sciences, Engineering, and Medicine (NASEM) report comprehensively evaluated the body of evidence regarding cannabis health effects through the year 2016. The objectives of this study are to identify and map the most recently (2016–2019) published literature across approved conditions for medical cannabis and to evaluate the quality of identified recent systematic reviews, published following the NASEM report.
Media
Publications:
Documents:
Videos:
Audio/Podcasts:
Social